Total Payments
$12,966
2024 Payments
$1,560
Companies
42
Transactions
617
Medicare Patients
9,048
Medicare Billing
$534,653
Payment Breakdown by Category
Food & Beverage$11,013 (84.9%)
Travel$1,828 (14.1%)
Education$124.78 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,013 | 605 | 84.9% |
| Travel and Lodging | $1,828 | 5 | 14.1% |
| Education | $124.78 | 7 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Luitpold Pharmaceuticals Inc | $1,564 | 5 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,441 | 96 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,424 | 32 | $0 (2024) |
| Amgen Inc. | $1,280 | 85 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $917.02 | 56 | $0 (2024) |
| PFIZER INC. | $755.41 | 43 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $752.56 | 57 | $0 (2024) |
| Gilead Sciences, Inc. | $374.42 | 30 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $344.72 | 20 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $340.25 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,560 | 79 | Novartis Pharmaceuticals Corporation ($289.06) |
| 2023 | $1,464 | 77 | Novartis Pharmaceuticals Corporation ($219.02) |
| 2022 | $1,059 | 57 | Bayer HealthCare Pharmaceuticals Inc. ($156.81) |
| 2021 | $1,034 | 60 | Amgen Inc. ($208.91) |
| 2020 | $461.64 | 27 | Amgen Inc. ($73.39) |
| 2019 | $1,641 | 100 | Novartis Pharmaceuticals Corporation ($233.75) |
| 2018 | $2,451 | 102 | Merck Sharp & Dohme Corporation ($888.72) |
| 2017 | $3,295 | 115 | Luitpold Pharmaceuticals Inc ($1,564) |
All Payment Transactions
617 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $11.27 | General |
| Category: DIABETES | ||||||
| 11/22/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Cardiology | ||||||
| 11/20/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $23.06 | General |
| Category: Cardiovascular | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $31.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: DIABETES | ||||||
| 11/12/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Cardiology | ||||||
| 11/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: DIABETES | ||||||
| 10/11/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/08/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Not Applicable | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $6.94 | General |
| Category: DIABETES | ||||||
| 09/25/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $30.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/13/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Cardiology | ||||||
| 09/06/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/02/2024 | Boston Scientific Corporation | LUX-Dx Insertable Cardiac Monitor (Device) | Food and Beverage | In-kind items and services | $53.10 | General |
| Category: LUX-Dx_CRM | ||||||
| 08/30/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,719 | 2,348 | $548,402 | $126,139 |
| 2022 | 23 | 2,535 | 3,385 | $593,344 | $142,335 |
| 2021 | 25 | 2,219 | 3,014 | $489,062 | $131,059 |
| 2020 | 25 | 2,575 | 3,101 | $442,021 | $135,120 |
Total Patients
9,048
Total Services
11,848
Medicare Billing
$534,653
Procedure Codes
102
All Medicare Procedures & Services
102 procedure records from CMS Medicare Utilization — Page 3 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 290 | 420 | $99,756 | $36,722 | 36.8% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 149 | 157 | $104,316 | $21,694 | 20.8% |
| 93880 | Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck | Office | 2021 | 87 | 88 | $34,109 | $13,272 | 38.9% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 186 | 188 | $33,727 | $9,972 | 29.6% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2021 | 14 | 42 | $14,167 | $6,924 | 48.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 65 | 66 | $16,010 | $6,844 | 42.7% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 772 | 1,016 | $34,661 | $6,021 | 17.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 338 | 433 | $49,752 | $4,390 | 8.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 26 | 26 | $6,632 | $3,295 | 49.7% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2021 | 16 | 30 | $3,920 | $2,878 | 73.4% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2021 | 16 | 64 | $4,716 | $2,840 | 60.2% |
| 93284 | Evaluation, testing and programming adjustment of defibrillator with analysis, review and report, multiple lead defibrillator system | Office | 2021 | 14 | 34 | $13,425 | $2,752 | 20.5% |
| 93280 | Evaluation, testing, and programming adjustment of permanent dual lead pacemaker system with physician analysis, review, and report | Office | 2021 | 27 | 47 | $11,278 | $2,644 | 23.4% |
| 93978 | Ultrasound scan of vena cava or groin graft or vessel blood flow | Office | 2021 | 13 | 13 | $4,319 | $1,774 | 41.1% |
| 99219 | Hospital observation care, typically 50 minutes | Facility | 2021 | 15 | 15 | $3,290 | $1,572 | 47.8% |
| 93312 | Insertion of probe in esophagus for heart ultrasound examination including interpretation and report | Facility | 2021 | 18 | 19 | $5,005 | $1,545 | 30.9% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2021 | 17 | 18 | $25,671 | $1,460 | 5.7% |
| 93793 | Anti-clotting management for patient taking warfarin | Office | 2021 | 13 | 152 | $3,314 | $1,328 | 40.1% |
| 93290 | Evaluation of parameters of implantable heart and blood vessel monitor system with qualified health care professional analysis, review, and report | Office | 2021 | 17 | 29 | $4,842 | $1,018 | 21.0% |
| 93298 | Remote evaluations of heart rhythm monitor system implanted under skin with qualified health care professional analysis, review, and report, up to 30 days | Office | 2021 | 14 | 42 | $3,788 | $817.05 | 21.6% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2021 | 15 | 15 | $1,367 | $300.30 | 22.0% |
| 93320 | Doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2021 | 18 | 19 | $1,900 | $257.04 | 13.5% |
| 93296 | Remote evaluations of single, dual, or multiple lead pacemaker system or implantable defibrillator system with technician review, support and distribution of results, up to 90 days | Office | 2021 | 11 | 12 | $2,279 | $236.04 | 10.4% |
| 93225 | Heart rhythm tracing of 48-hour ekg | Office | 2021 | 15 | 15 | $1,724 | $208.04 | 12.1% |
| 93227 | Heart rhythm tracing, analysis, and interpretation of 48-hour ekg | Office | 2021 | 16 | 16 | $2,404 | $207.62 | 8.6% |
About Dr. Michael Hong, MD
Dr. Michael Hong, MD is a Cardiovascular Disease healthcare provider based in Buffalo, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760595771.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Hong, MD has received a total of $12,966 in payments from pharmaceutical and medical device companies, with $1,560 received in 2024. These payments were reported across 617 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($11,013).
As a Medicare-enrolled provider, Hong has provided services to 9,048 Medicare beneficiaries, totaling 11,848 services with total Medicare billing of $534,653. Data is available for 4 years (2020–2023), covering 102 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Buffalo, NY
- Active Since 08/16/2006
- Last Updated 12/01/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760595771
Products in Payments
- INJECTAFER (Drug) $1,593
- ENTRESTO (Drug) $1,125
- Repatha (Biological) $1,067
- MK-1242 (Drug) $888.72
- XARELTO (Drug) $752.56
- ELIQUIS (Drug) $653.18
- JARDIANCE (Drug) $564.60
- VERQUVO (Drug) $517.55
- PRADAXA (Drug) $352.42
- BRILINTA (Drug) $306.48
- LEQVIO (Drug) $300.88
- Corlanor (Drug) $212.62
- PRALUENT (Drug) $209.36
- LifeVest (Device) $209.00
- Impella (Device) $194.35
- CHANTIX (Drug) $171.99
- Arcalyst (Drug) $156.51
- Kerendia (Drug) $145.77
- MULTAQ (Drug) $135.36
- Hillrom - Cardiac Ambulatory Monitor (Device) $123.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Buffalo
Dr. Kenton Forte, M.d, M.D
Cardiovascular Disease — Payments: $475,136
Cardiovascular Disease $475,136
William Boden, Md, MD
Cardiovascular Disease — Payments: $244,563
Cardiovascular Disease $244,563
Anne Curtis, Md, MD
Cardiovascular Disease — Payments: $227,013
Cardiovascular Disease $227,013
Dr. Salvatore Calandra, Md, MD
Cardiovascular Disease — Payments: $72,862
Cardiovascular Disease $72,862
Dr. Stanley Fernandez, M.d, M.D
Cardiovascular Disease — Payments: $53,366
Cardiovascular Disease $53,366
Joseph Gelormini, M.d, M.D
Cardiovascular Disease — Payments: $14,839
Cardiovascular Disease $14,839